|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
MX2014001222A
(es)
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
IL305629A
(en)
|
2013-02-15 |
2023-11-01 |
Univ California |
Chimeric antigen receptor and methods of using it
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
EP3104866A4
(en)
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
|
DK3105335T3
(da)
|
2014-02-14 |
2020-01-13 |
Univ Texas |
Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
|
|
CN120536341A
(zh)
|
2014-03-04 |
2025-08-26 |
菲特治疗公司 |
改良的重编程方法和细胞培养平台
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
AU2015312117A1
(en)
|
2014-09-02 |
2017-03-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
|
|
WO2016126608A1
(en)
*
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016149665A1
(en)
|
2015-03-18 |
2016-09-22 |
Baylor College Of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
ES2909973T3
(es)
|
2015-11-04 |
2022-05-10 |
Hope City |
Receptores quiméricos para el antígeno que se dirigen a HER2
|
|
CA3007473A1
(en)
|
2015-12-14 |
2017-06-22 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
US12247226B2
(en)
|
2017-10-11 |
2025-03-11 |
Fate Therapeutics, Inc. |
Cellular reprogramming using temporal and transient plasmid vector expression system
|
|
KR102774451B1
(ko)
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
CN111556892A
(zh)
|
2017-12-08 |
2020-08-18 |
菲特治疗公司 |
使用增强的iPSC衍生的效应细胞的免疫疗法
|
|
BR112020011017A2
(pt)
|
2017-12-22 |
2020-11-17 |
Fate Therapeutics, Inc. |
células efetoras imunes intensificadas e uso das mesmas
|
|
SG10201801219VA
(en)
*
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
EP3824075A4
(en)
|
2018-07-17 |
2022-04-20 |
The Regents of The University of California |
CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
JP2022525928A
(ja)
|
2019-03-21 |
2022-05-20 |
ガミダ セル リミテッド |
併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
|
|
EP3941947A4
(en)
*
|
2019-03-22 |
2022-12-14 |
Olivia Newton-John Cancer Research Institute |
ANTI-HER2 BINDING MOLECULES
|
|
KR20220035190A
(ko)
|
2019-07-17 |
2022-03-21 |
페이트 세러퓨틱스, 인코포레이티드 |
면역 효과기 세포 조작 및 이의 용도
|
|
US20220378831A1
(en)
|
2019-09-25 |
2022-12-01 |
Fate Therapeutics, Inc. |
Multi-targeting effector cells and use thereof
|
|
EP4041759A4
(en)
|
2019-10-07 |
2023-12-20 |
Fate Therapeutics, Inc. |
IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE
|
|
EP4045539A4
(en)
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
JP7879804B2
(ja)
|
2019-12-06 |
2026-06-24 |
フェイト セラピューティクス，インコーポレイテッド |
小化合物を使用するｉＰＳＣ由来エフェクター免疫細胞の増強
|
|
CN115485293A
(zh)
|
2020-01-23 |
2022-12-16 |
埃克苏马生物技术公司 |
用于her2的嵌合抗原受体和其使用方法
|
|
WO2021235894A1
(en)
|
2020-05-22 |
2021-11-25 |
Green Cross Lab Cell Corporation |
Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same
|
|
WO2022098914A1
(en)
|
2020-11-04 |
2022-05-12 |
Fate Therapeutics, Inc. |
Engineered ipsc and persistent immune effector cells
|
|
US20230405121A1
(en)
|
2020-11-04 |
2023-12-21 |
Fate Therapeutics, Inc. |
Engineered ipsc and immune effector cells for heterogenous tumor control
|
|
CN112391414A
(zh)
|
2020-11-17 |
2021-02-23 |
中国医学科学院基础医学研究所 |
一种靶向her2的car-t表达载体及其构建和应用
|
|
EP4253420A4
(en)
*
|
2020-11-30 |
2024-11-06 |
ONO Pharmaceutical Co., Ltd. |
HER2 TARGETING AGENT
|
|
KR20250004622A
(ko)
|
2022-04-08 |
2025-01-08 |
페이트 세러퓨틱스, 인코포레이티드 |
종양 표적화를 위한 키메라 항원 수용체
|